3:02 PM
 | 
Dec 27, 2018
 |  BC Extra  |  Company News

China’s NMPA approves Innovent’s PD-1 mAb Tyvyt for Hodgkin lymphoma

China's National Medical Products Administration approved anti-PD-1 mAb Tyvyt sintilimab (IBI308) from Innovent Biologics Inc. (HKSE:1801) to treat relapsed or refractory classical Hodgkin lymphoma. Tyvyt brings the country's slate of approved PD-1 inhibitors to at least four, covering three indications.

Co-developed by Innovent and Eli Lilly and Co. (NYSE:LLY), Tyvyt is Innovent's first approved therapy....

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >